Small-molecule targeted agents: new choices for the treatment of psoriasis
- VernacularTitle:小分子靶向药物：银屑病治疗的新选择
- Author:
Chen YU
1
;
Gang WANG
Author Information
- Keywords: Psoriasis; Phosphodiesterase 4 inhibitors; Janus kinase inhibitors; Tyrosine kinase 2 inhibitors; Small molecules
- From: Chinese Journal of Dermatology 2022;55(9):747-751
- CountryChina
- Language:Chinese
- Abstract: With the rapid development of immunology and molecular biology in recent years, great progress has been made in the research on psoriatic pathogenesis, as well as in therapeutic strategies targeting key molecules in the pathogenesis. In addition to biologics, small-molecule targeted agents for psoriasis have also received increasing attention, especially agents targeting phosphodiesterase 4, Janus kinase, and tyrosine kinase 2, etc. An increasing number of small-molecule drug candidates have shown favorable efficacy in clinical studies, and some of them have been approved for clinical application and play a unique role in the treatment of psoriasis.
